Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence
Pooled result · Overall drug discontinuationResult — go to the resultPooled hazard ratio 0.72 95% CI 0.61–0.85Authors' conclusion
Real-world evidence indicates that selective JAK1 inhibitors offer better drug retention than pan-JAK inhibitors in RA patients, primarily due to sustained effectiveness rather than differences in safety profiles.
Study context
- Population
- Adult rheumatoid arthritis (RA) patients in real-world practice, Europe, Asia and the United States
- Participants
- 21,244 patients7 studies
- Comparison
- Selective JAK1 inhibitors vs pan-JAK inhibitors
- Outcome
- Overall risk of drug discontinuation
Methodological detailsregistry-based cohorts and claims database studies, random-effects model
- Registry-based cohorts and claims database studies
- Random-effects model
Pooled result
Overall drug discontinuation
Pooled hazard ratio
0.72
95% CI 0.61–0.85
P < 0.001
Selective JAK1 inhibitorsvs Pan-JAK inhibitors
pooled HR 0.72 (95% CI 0.61–0.85); P < 0.001
As reported in the abstract
Further pooled results
| Outcome | Pooled HR (95% CI) | P value | |
|---|---|---|---|
| Discontinuation due to lack of efficacy (subgroup) | 0.68 (0.55–0.84) | P < 0.01 | |
| 0.512Pooled hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence. Semin Arthritis Rheum. Published 21 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →